Stroke Care during the COVID-19 Pandemic; A Global Challenge
نویسندگان
1 Assistant Professor, Division of Stroke and Endovascular Neurosurgery, Department of Neurological Surgery , University of Southern California(USC), Los Angeles, CA, USA
doi
10.30476/ijms.2020.87678.1815چکیده
Acute Ischemic stroke (AIS) is one of the major causes of mortality and disability globally. Up to the present time, thrombolysis with intravenous (IV) recombinant tissue plasminogen activator (rtPA) is the only FDA-approved pharmacological treatment for AIS. Moreover; several randomized clinical trials have endorsed the benefits of endovascular treatment (EVT) with stent retrievers in strokes with large vessel occlusion by improving the overall functional outcome and reducing mortality.3 The benefits of IV rtPA and EVT in AIS are highly time-dependent and the American Stroke Association guidelines recommend treating the patients with AIS as quickly as possible.
